Read more
Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves - such as bisphosphonates, antiresorptives and anabolic agents - within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs in future treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.
List of contents
Introduction.- Developmental Pharmacokinetics: Drug Disposition Relative to Age.- Drug Development for Pediatric Diseases with Bone Loss.- Pediatric Bone Physiology and Monitoring Safety and Efficacy of Bone Drugs in Children.- Bisphosphonates in Osteogenesis Imperfecta.- Use of Bisphosphonates in Genetic Diseases Other Than Osteogenesis Imperfecta.- Bisphosphonates in Pediatric Burn Injury.- Growth Hormone and Bone.- Growth Hormone and Oxandrolone in Burned Children.- Pediatric Bone Drugs: Calcium and Vitamin D.- Pediatric Maxillofacial Conditions and Drugs.- Newer Adult Bone Drugs.- Conclusion: Whither (or Wither?) the Pharmacology on Pediatric Bone?.
About the author
Gordon L. Klein, MD, MPH, Department of Orthopaedic Surgery, University of Texas Medical Branch, Galveston, TX, USA.
Summary
Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves – such as bisphosphonates, antiresorptives and anabolic agents – within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs in future treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.
